Evidence map›Paper›PMID 35613072›Full record

ArticlePLoS neglected tropical diseases2022

Emergence of multi-drug-resistant Mycobacterium tuberculosis in Niger: A snapshot based on whole-genome sequencing.

Zelika Harouna Hamidou, Madjid Morsli, Saidou Mamadou, Michel Drancourt, Jamal Saad

Abstract read
In one paragraph

Article in PLoS neglected tropical diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Zelika Harouna HamidouAix-Marseille-Univ, IRD, MEPHI, IHU Méditerranée Infection, Marseille, France.ORCID 0000-0002-1546-708X
Madjid MorsliAix-Marseille-Univ, IRD, MEPHI, IHU Méditerranée Infection, Marseille, France.ORCID 0000-0002-8074-1794
Saidou MamadouLaboratoire National de Référence des IST/VIH et de la Tuberculose, Niamey, Niger.ORCID 0000-0001-5142-5322
Michel DrancourtAix-Marseille-Univ, IRD, MEPHI, IHU Méditerranée Infection, Marseille, France.
Jamal SaadAix-Marseille-Univ, IRD, MEPHI, IHU Méditerranée Infection, Marseille, France.ORCID 0000-0002-6187-5893

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAmong other West African countries experiencing the high endemicity of deadly tuberculosis, the situation in Niger is poorly evidenced by microbiological investigations. METHODOLOGY/PRINCIPAL

findingsThe study of 42 isolates of Mycobacterium tuberculosis from Niger by whole genome sequencing using Illumina iSeq technology yielded four M. tuberculosis lineages: Indo-Oceanic L1 (n = 1) (2.3%), East-Asian (n = 1) (2.3%), East-African Indian L3 (n = 2) (4.7%) and Euro-American L4 (n = 38) (90.4%). The sub-lineage L4.1.3 comprising 18 isolates (47.3%) was predominant, followed by the L4.6.2.2 sub-lineage (Cameroon genotype, n = 13 isolates) (34.2%). Investigating drug resistance profile for 12 antibiotics found 8/42 (19%) pan-susceptible isolates and 34/42 (81%) resistant isolates; with 40/42 (95.2%) isolates being susceptible to clofazimine-bedaquiline. CONCLUSIONS/SIGNIFICANCE: These unprecedented data from Niger highlight the dynamics of tuberculosis transmission and drug resistance in Niger and may assist tuberculosis control in this country which continues to support a high burden of tuberculosis.

Indexed as

AsteraceaeMycobacterium tuberculosisTuberculosis, Lymph NodeTuberculosis, Multidrug-ResistantAntitubercular AgentsGenotypeHumansNigerPhylogenyWhole Genome SequencingAntitubercular Agents

Identifiers

PMID35613072
PMCPMC9132302

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.